- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01271309
Stem Cell Migratory Activity: Prognostic Marker in Myocardial Ischemia
Migratory and Angiogenic Dysfunction of Circulating CD133 Stem Cells: a New Prognostic Marker in Myocardial Ischemia.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
MAIN OBJECTIVES OF THE STUDY:
Characterization of circulating CD133+ stem cells in a group of 170 patients with MI (mean post-MI follow up, 6 months):
- Counting total mononuclear cells and FACS analysis of CD133 stem cells.
- Characterization of CD133+ stem cell biology: Migratory assay, imaging of cytoskeleton, angiogenesis tests in vitro.
- Evaluation of migratory signalling, with specific focus on the PI3K/Akt/eNOS system.
Assessment of the prognostic value of the stem cell migration assay.
- Relationship between cell biology tests on CD133+ cells and changes in circulating cytokines and pro-angiogenic factors after MI.
- Assessment of area at risk by ECG-synchronized Single Photon Emission Computed Tomography (gated-SPECT) in subgroups with different patterns of stem cell migratory tests.
- Assessment of ventricular remodelling (echocardiography, NMR) in relation with patterns of stem cell migratory test.
EXPECTED RESULTS:
Clarification of the implication of stem cell migratory deficit in post-ischemic HF.
- Identification of underlying mechanisms
- Identification of a cellular marker for prediction of patients at risk of HF.
RELEVANCE TO PUBLIC HEALTH:
- Introduction of a biological test for the early diagnosis of post-MI HF
- Recognition of therapeutic targets for the rescue of stem cell migratory liabilities
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Ferrara, Italia
- Cardiology Dept. Arcispedale S.Anna
-
Milan, Italia
- IRCCS Multimedica
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients will be recruited sequentially at the Operative Unit of Ferrara having the following characteristics: Thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG. MI will be confirmed by elevation of troponin I and CK-MB. Patients will be treated according to international guidelines. With regard to medical treatment, this will include all available drugs except for statins, which will be inserted only 14 days post-MI, to avoid the confounding effect of these drugs on stem cell biology.
Patients reporting thoracic pain 24 hours prior to hospitalization will be excluded. Similarly, those with HF symptoms resistant to therapy will be excluded. By contrast, patients with Killip II e III LV dysfunction will be included.
Beskrivelse
Inclusion Criteria:
- Age >= 18 years
- Thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG.
- MI confirmed by elevation of troponin I and CK-MB.
- Patients with Killip II e III LV dysfunction will be included.
Exclusion Criteria:
- Patients reporting thoracic pain 24 hours prior to hospitalization
- HF symptoms resistant to therapy
- Haemoglobin< 10 gr/dl
- Haemodynamic instability (systolic pressure <90 mmHg after treatment)
- Alterations in haematopoiesys
- Concurrent neoplastic disease
- No written informed consent or other conditions that affect patient's compliance to protocol.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Acute Myocardial Infarction patients
Patients with thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Prognostic value of CD133+ stem cells in MI
Tidsramme: 12 months
|
Correlation of clinical parameters of disease evolution and biological features
|
12 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Correlation of disease evolution and other biomarkers
Tidsramme: 12 months
|
12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Marco Valgimigli, MD, University Ferrara Hospital
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 05/2007_Ferrara
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hjerteinfarkt
-
Kitasato UniversityRekrutteringAterosklerose | Akutt koronarsyndrom | Stabil angina | Koronar; Iskemisk | STEMI - ST-segment Elevation Myocardial Infarction | NSTEMI - Non-ST-Segment Elevation Myocardial InfarctionJapan
-
University Hospital, Strasbourg, FranceAvsluttetST Elevatation Myocardial Infarction (STEMI)Frankrike
-
VesalioRekrutteringSegment Elevation Myocardial Infarction (STEMI)Sveits
-
AstraZenecaFullførtHjerteinfarkt | Segment Elevation Myocardial Infarction (STEMI)Australia, Frankrike, Italia, Spania, Storbritannia, Sverige, Tyskland, Ungarn, Danmark, Østerrike, Canada, Nederland, Algerie
-
Capital Medical UniversityFullførtTransradial Approach, Primær PCI, ST-segment Elevation Myocardial InfarctionKina
-
University of Southern CaliforniaAktiv, ikke rekrutterendeNSTEMI - Ikke-ST Segment Elevation MI | Akutt koronarsyndrom (ACS) | STEMI - ST Elevation Myocardial Infarction (MI) | Ustabil angina (UA)Forente stater
-
Izmir Bakircay UniversityFullførtMyocardial Bridge of Coronary ArteryTyrkia
-
ITAB - Institute for Advanced Biomedical TechnologiesAzienda Ospedaliero, Universitaria Ospedali RiunitiFullførtMyocardial Bridge of Coronary ArteryItalia
-
Sichuan Provincial People's HospitalPåmelding etter invitasjonRest Gated Myocardial Perfusion Imaging ved hjertesviktKina
-
Azienda Ospedaliero Universitaria Maggiore della...Università degli Studi del Piemonte Orientale "Amedeo Avogadro"Rekruttering